Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast Cancer

Sara M. Tolaney, MD, MPH
Published: Wednesday, Aug 30, 2017



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy for patients with breast cancer.

Since 2013, pertuzumab (Perjeta)-based chemotherapy has dominated the treatment landscape in the preoperative setting, based on the results of the NeoSphere and TRYPHAENA trials, states Tolaney.

However, now there are data from the APHINITY trial looking at the long-term benefits of pertuzumab in the adjuvant setting. Since the results of this trial demonstrate that not all patients will experience a long-term benefit with pertuzumab, this could potentially change the approach to treatment in the neoadjuvant setting.
 
SELECTED
LANGUAGE


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy for patients with breast cancer.

Since 2013, pertuzumab (Perjeta)-based chemotherapy has dominated the treatment landscape in the preoperative setting, based on the results of the NeoSphere and TRYPHAENA trials, states Tolaney.

However, now there are data from the APHINITY trial looking at the long-term benefits of pertuzumab in the adjuvant setting. Since the results of this trial demonstrate that not all patients will experience a long-term benefit with pertuzumab, this could potentially change the approach to treatment in the neoadjuvant setting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x